Clinical trial Recruiting at 1 site Observational Ages 10 to 65 Women only

Understanding Premature Ovarian Insufficiency: Observations from Multiple Hospitals

Official title: A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency

Run by Women's Hospital School Of Medicine Zhejiang University · NCT06067529 · Data updated 2026-11-12

This study tests how POI develops and affects health by tracking women with POI across several centers.

Quick facts

Study typeObservational
Ages10 Years to 65 Years
SexWomen only
Enrollment1080 (estimated)
SponsorWomen's Hospital School Of Medicine Zhejiang University
Academic / other
Drugs / interventionschemotherapy
Locations2 sites (Hangzhou, Zhejiang and 1 other locations)
StatusRecruiting
StartedOctober 10, 2023
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedMay 28, 2026
Trial IDNCT06067529 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women diagnosed with POI under 40 years of age who are willing to participate and provide biological samples.

Probably not a fit

Patients who do not experience changes in POI risk factors or health outcomes may not directly benefit from the results.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a hospital-based, multicenter observational study that follows women with POI over time to describe disease characteristics, risk factors, and health outcomes. It will collect information on lifestyle, environment, and biological samples to observe natural progression and health impacts. The study constructs case-control and prospective cohorts to analyze how POI influences overall health and disease risk, aiming to inform clinical decisions. Participation involves baseline assessment, follow-up visits, and long-term data collection. No experimental interventions are involved.

Why it matters

Potential benefit: If successful, findings could improve understanding of POI risk factors and health effects, potentially guiding diagnosis and management.

How similar studies have gone: Previous observational work has explored POI risk factors and health impact, but comprehensive multi-center prospective data are limited, making this study relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Women with POI

1. Inclusion Criteria 1.1 Age at Diagnosis: Less than 40 years of age. 1.2 Diagnosis of POI: Met one of the following diagnostic criteria based on ESHRE guidelines: Spontaneous POI: Oligomenorrhea or amenorrhea for at least 4 months, combined with elevated FSH levels (\> 25 IU/L) on two occasions at least 4 weeks apart.

   Iatrogenic POI: Documented history of bilateral oophorectomy, or ovarian failure resulting from chemotherapy or radiotherapy.

   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and complete long-term follow-up assessments.
2. Exclusion Criteria 2.1 Current Pregnancy or Lactation: Women who were pregnant or breastfeeding at the time of enrollment.

2.2 Severe Systemic Conditions: Presence of severe somatic or psychiatric diseases (e.g., active malignancy not related to POI, severe heart/renal failure, or cognitive impairment) that would preclude adherence to the study protocol or long-term follow-up.

Control

1. Inclusion Criteria:

   1.1 Age: 18-50 years. 1.2 Menstrual History: Regular menstrual cycles (21-35 days) for the past 12 months.

   1.3 Consent: Willingness to participate, provide biological samples, and provide written informed consent.
2. Exclusion Criteria:

2.1 Physiological Status: Pregnancy, breastfeeding, or clinical perimenopause/postmenopause.

2.2 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.

2.3 Iatrogenic \& Toxic Factors: Prior ovarian surgery (e.g., cystectomy), chemotherapy, or radiotherapy.

2.4 Systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, or hematological diseases, or malignancy.

2.5 Genetic \& Familial Background: First-degree relatives with POI or early menopause (\< 45 years). Family history of hereditary diseases. 2.6 Medication: Use of hormonal drugs or contraceptives within the last 6 months.

Ovarian Surgery group

1. Inclusion Criteria:

   1.1 Age: 18-60 years. 1.2 Patients with ovarian surgery: women scheduled to undergo ovarian surgery for gynecological disease.

   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and sign the informed consent.
2. Exclusion Criteria:

2.1 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.

2.2 Medication: Use of hormonal drugs or contraceptives within the last 6 months.

2.3 Genetic or chromosomal abnormalities: Turner syndrome, or other genetic disease.

2.4 Physiological Status: Pregnancy, breastfeeding, or seeking the help of assisted reproductive technology.

2.5 Severe systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, hematological diseases, malignancy, or cognitive impairment.

Oophorectomy group

1. Inclusion Criteria:

   1.1 Age: 45-65 years. 1.2 Patients with oophorectomy: women scheduled to undergo oophorectomy due to gynecological diseases and met criteria for being menopausal.

   1.3 Menopausal status: at least 12 consecutive months of amenorrhea without other medical causes.

   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and sign the informed consent.
2. Exclusion Criteria:

2.1 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.

2.2 Medication: Use of hormonal drugs or contraceptives within the last 6 months.

2.3 Genetic or chromosomal abnormalities: Turner syndrome, or other genetic disease 2.4 Physiological Status: Pregnancy, breastfeeding, or seeking the help of assisted reproductive technology.

2.5 Severe systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, hematological diseases, malignancy, or cognitive impairment.

Where it's running

  • Women's Hospital School of Medicine Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting
  • Women's Hospital School of Medicine Zhejiang University
    Hangzhou, Zhejiang, China
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Autologous Hair Follicle Secretome + PRP for POI

    This pilot study tests whether a patient’s own hair follicle secretome combined with their own platelet-rich plasma can improve ovarian function in women with premature ovarian insufficiency.

    Recruiting Phase 2 Trio Fertility · Toronto, Ontario · NCT07916740

  • Intravenous hUC-MSCs for POI: Safety, Tolerability and Early Efficacy

    We’re testing whether IV human umbilical cord mesenchymal stem cells can be safely given to women under 40 with premature ovarian insufficiency to see if it helps improve ovarian function.

    Recruiting Phase 1/2 Shenzhen Wingor Biotechnology Co., Ltd. · Beijing, Beijing Municipality · NCT07775391

  • Human amniotic mesenchymal stem cell treatment for premature ovarian insufficiency

    This trial will test whether an intravenous infusion of human amniotic mesenchymal stem cells combined with standard hormone therapy can help women under 40 with premature ovarian insufficiency.

    Recruiting Phase 1/2 Changhai Hospital · Shanghai · NCT07115082

  • Hormone replacement for adolescents with premature ovarian insufficiency

    This study will test estrogen patches plus progesterone in girls and young women aged 11–19 with premature ovarian insufficiency to see if hormone replacement improves bone density, metabolic markers, muscle strength, and cardiovascular health.

    Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06851754

  • Using Platelet-rich Plasma to Improve Female Fertility

    This study is testing whether injections of platelet-rich plasma can help improve fertility in women dealing with issues like poor ovarian response and repeated implantation failure.

    Recruiting The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Yiwu, Zhejiang · NCT06645379

  • Using fat-derived cells to treat premature ovarian insufficiency

    This study is testing if using fat-derived cells can help improve pregnancy chances for women with premature ovarian insufficiency compared to standard IVF treatments.

    Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT06481969

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.